Pre-beta HDL Particles for Amyloid Beta Peptide Drainage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating cerebral amyloid angiopathy, Alzheimer’s disease, and acute stroke are limited by the inability to effectively remove amyloid beta peptides from the bloodstream before they cross the blood-brain barrier, and existing apheresis systems are inefficient in reducing lipid levels in blood components.
Innovation Solution
A method involving the creation of pre-beta HDL particles by selectively removing lipids from HDL particles using a lipid removing agent, which are then administered to patients to facilitate the drainage of amyloid beta peptides and other soluble oligomers, while maintaining LDL particles intact, and the use of CETP inhibitors to enhance HDL function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If apheresis systems are used to reduce lipid levels in blood components, then lipid levels are reduced, but the systems are inefficient and cannot effectively remove amyloid beta peptides from the bloodstream
Solution Approach 1:
The patent extracts and isolates amyloid beta peptides from the bloodstream using selective binding agents that specifically target and remove these peptides, separating them from other blood components including lipids, thereby achieving efficient amyloid removal independent of traditional apheresis lipid reduction capabilities
Solution Approach 2:
The patent introduces intermediary substances such as selective binding agents or carrier molecules that mediate the removal process by binding to amyloid beta peptides and facilitating their extraction from blood, overcoming the inefficiency of direct apheresis methods
2Productivity
If HDL particles are modified to create pre-beta HDL, then amyloid drainage capability is enhanced, but the complexity of particle creation increases
Solution Approach 1:
The patent modifies physical or chemical parameters of HDL particles, such as lipid composition or surface properties, to transform them into pre-beta HDL with enhanced amyloid binding and drainage capabilities, achieving functional enhancement through parameter optimization rather than complex structural redesign
Solution Approach 2:
The patent creates asymmetric modifications in HDL particles by selectively altering specific regions or components of the particles to enhance amyloid interaction while preserving other functional aspects, thereby improving drainage capability without requiring complete restructuring of the particle system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively delays the progression, stabilizes, or improves symptoms of cerebral amyloid angiopathy and Alzheimer’s disease by reducing amyloid plaque accumulation and improving cognitive function, while also addressing the inefficiencies of existing treatments.
Implementation Method 1
selectively removing lipids from HDL particles using a lipid removing agent
Implementation Method 2
administered to patients to facilitate the drainage of amyloid beta peptides and other soluble oligomers
Data Source
AI summary
Systems, apparatuses and methods for prophylactically preventing, or for treating the onset and/or progression of Cerebral Amyloid Angiopathy (CAA), acute stroke conditions, or Alzheimer’s disease include the administration to a patient pre-beta HDL particles, a CETP inhibitor, or a combination of both pre-beta HDL particles and a CETP inhibitor. The progression of, stabilizing, or improving symptoms related to these conditions are treated by monitoring a pathophysiological change indicative of the conditions in a patient, based on the monitoring, determining if amyloid plaque is present in a perivascular space/IPAD System/Perivascular Pathway of the patient, optionally determining an extent of amyloid plaque in the perivascular space/IPAD System/Perivascular Pathway, and based on the presence of amyloid plaque in the perivascular space/IPAD System/Perivascular Pathway of the patient, determining a treatment protocol for the patient. The treatment protocol includes administering to the patient a high density lipoprotein composition derived from mixing a blood fraction with a lipid removing agent, wherein the high density lipoprotein composition comprises pre-beta HDL, administering to the patient a CETP inhibitor, or administering to the patient both the high density lipoprotein composition and the CETP inhibitor.